Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.17NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.258.22NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.258.22NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AG.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AG.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.258.16NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.258.16NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
W.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
W.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.264.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.264.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.190NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.190NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.552NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.552NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.13.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.13.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-1668.53US
GW.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GW.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.424NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.424NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.64NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.64NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AH.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AH.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.327NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.327NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.4.6.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.4.6.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBJNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBJNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EJ.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EJ.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DQ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DQ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.63NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.63NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FM.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FM.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GA.4.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GA.4.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GK.1.10.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GK.1.10.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.10NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GN.1.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used